Cargando…

The research status of immune checkpoint blockade by anti-CTLA4 and anti-PD1/PD-l1 antibodies in tumor immunotherapy in China: A bibliometrics study

PURPOSE: Using bibliometrics, we analyzed the research status of immune checkpoint blockade (ICB, a popular tumor immunotherapy method represented by antibodies targeted CTLA-4 and PD-1/PD-L1) in tumor immunotherapy in China during the past 2 decades. METHODS: Articles in Science Citation Index Expa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Xiaoqin, He, Liangmei, Mao, Kaiyun, Chen, Daming, Jiang, Hongbo, Liu, Zhiping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2018
Materias:	3600
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908611/ https://www.ncbi.nlm.nih.gov/pubmed/29642147 http://dx.doi.org/10.1097/MD.0000000000010276

Ejemplares similares

Characterization of PD-1/PD-L1 immune checkpoint expression in the pathogenesis of musculoskeletal Langerhans cell histiocytosis: A retrospective study
por: Hashimoto, Kazuhiko, et al.
Publicado: (2021)

PD-1/PD-L1 pathway activation restores the imbalance of Th1/Th2 and treg/Th17 cells subtypes in immune thrombocytopenic purpura patients
por: Wu, Die, et al.
Publicado: (2019)

Immune-related adverse events associated with PD-1 and PD-L1 inhibitors for nonsmall cell lung cancer: Protocol for a systematic review and meta-analysis
por: Sun, Xiaoying, et al.
Publicado: (2017)

Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma
por: Li, Zhu, et al.
Publicado: (2016)

Higher Frequency of CD4(+)CXCR5(+)ICOS(+)PD1(+) T Follicular Helper Cells in Patients With Infectious Mononucleosis
por: Liu, Jinlin, et al.
Publicado: (2015)

Expression and clinical significance of PD-L1 and infiltrated immune cells in the gastric adenocarcinoma microenvironment
por: Quan, Qiuying, et al.
Publicado: (2023)

T lymphocyte subsets and PD-1 expression on lymphocytes in peripheral blood of patients with non-small cell lung cancer
por: Chen, Tingting, et al.
Publicado: (2022)

Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study
por: Sun, Yiting, et al.
Publicado: (2021)

Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy
por: Tan, Shuguang, et al.
Publicado: (2016)

Positron Emission Tomography scanning in Anti-Neutrophil Cytoplasmic Antibodies-Associated Vasculitis
por: Kemna, Michael J., et al.
Publicado: (2015)

Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
por: Wei, Spencer C., et al.
Publicado: (2019)

The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition
por: Kreidieh, Firas Y., et al.
Publicado: (2023)

Study on the correlation between anti-ribosomal P protein antibody and systemic lupus erythematosus
por: Wang, Yanping, et al.
Publicado: (2020)

Clinical significance of HEp-2 cell cytoplasmic patterns in anti-neutrophil cytoplasmic antibody associated vasculitis
por: Zhang, Naidan, et al.
Publicado: (2022)

Mapping current status and emerging trends in NETosis: A bibliometric study
por: Wang, Hongqin, et al.
Publicado: (2023)

Evaluation of the 101 most cited immunology articles: A bibliometric analysis
por: Yilmaz Hanci, Sevgi
Publicado: (2023)

Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy
por: Krueger, Janna, et al.
Publicado: (2021)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1
por: Kong, Yi-chi M., et al.
Publicado: (2014)

Systemic Anti–PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid
por: Portnow, Jana, et al.
Publicado: (2020)

Frontier and hotspot evolution in Wiskott–Aldrich syndrome: A bibliometric analysis from 2001 to 2021
por: Liu, Shixu, et al.
Publicado: (2022)

A case report dysregulated neutrophil extracellular traps in a patient with propylthiouracil-induced anti-neutrophil cytoplasmic antibody-associated vasculitis
por: Watanabe-Kusunoki, Kanako, et al.
Publicado: (2019)

The value of anti-rods and rings antibodies in patients with nonhepatitis virus infection: A single-center retrospective study from Southwest China
por: Zhang, Naidan, et al.
Publicado: (2021)

Reprogramming Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 Therapy
por: Chen, Jiang, et al.
Publicado: (2023)

Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
por: O’Donnell, Jake S., et al.
Publicado: (2016)

Serum anti-PLA2R antibody and glomerular PLA2R deposition in Chinese patients with membranous nephropathy: A cross-sectional study
por: Pang, Lu, et al.
Publicado: (2017)

Efficacy of Anti-TNFα in Severe and Refractory Neuro-Behcet Disease: An Observational Study
por: Desbois, Anne Claire, et al.
Publicado: (2016)

Global research hotspots and frontier trends of epigenetic modifications in autoimmune diseases: A bibliometric analysis from 2012 to 2022
por: Gao, Xiang, et al.
Publicado: (2023)

Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy
por: Rose, April A N, et al.
Publicado: (2021)

Observation on the efficacy of sublingual immunotherapy with dust mite allergen for perennial allergic rhinitis and the mechanism of action on ILCs with ILC1s and ILC2s and ILC3s
por: Tang, Guangjun, et al.
Publicado: (2022)

The current management and biomarkers of immunotherapy in advanced gastric cancer
por: Chang, Xiaojing, et al.
Publicado: (2022)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
por: Wu, Bogang, et al.
Publicado: (2018)

Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis
por: Xiang, Ze, et al.
Publicado: (2022)

Impact of prophylactic TNF blockade in the dual PD-1 and CTLA-4 immunotherapy efficacy and toxicity
por: Alvarez, Maite, et al.
Publicado: (2019)

Immunotherapy of alveolar echinococcosis via PD‐1/PD‐L1 immune checkpoint blockade in mice
por: Wang, Junhua, et al.
Publicado: (2018)

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
por: Callahan, Margaret K., et al.
Publicado: (2015)

Antimesothelioma Immunotherapy by CTLA-4 Blockade Depends on Active PD1-Based TWIST1 Vaccination
por: Tan, Zhiwu, et al.
Publicado: (2020)

Research trends on anti-PD-1/PD-L1 immunotherapy for esophageal cancer: A bibliometric analysis
por: Yang, Yuanyuan, et al.
Publicado: (2022)

Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
por: Subrahmanyam, Priyanka B., et al.
Publicado: (2018)

Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?
por: Tang, Fei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qrpeemrdnbss6k4bt9ll0jrmtj